TY - JOUR
T1 - Is imidazoline site a unique receptor?A correlation with clonidine-displacing substance activity
AU - Atlas, Daphne
AU - Diamant, Sophia
AU - Zonnenschein, Ruth
PY - 1992/4
Y1 - 1992/4
N2 - Many specific hypotensive drugs acting via the central α2-adrenoceptors were designed based on their imidazoline.guanidine structure for use as antihypertensives. This unique structure, which is missing in the α2-adrenoceptor natural ligands, led to the search for an endogenous, nonadrenergic ligand, and later on, for its putative receptor.Indeed, an endogenous ligand designated the "clonidine displacing substance" (CDS), was isolated and purified from bovine brain, and characterized in various cells. The most intriguing feature of CDS is its hypertensive action upon injection into the rostral ventrolateral medulla and its competition with clonidine. Is CDS a natural agonist which is displaced by clonidine or other hypotensive drugs? Does the unique imidazoline.guanidine structure imply a unique recognition site?Recent studies reported that an imidazoline site, distinct from the α2-adrenoceptor, is abundant in many tissues, and it preferentially recognizes the imidazolino-guanidino type ligands.The physiological role of these sites is still not well defined. In the present study we show that the richest tissue in imidazoline sites is human placenta (1800 ± 100 fmol.mg protein). The sites are distributed on the cell surface, as observed in studies of binding to intact cytotrophoblasts and cultured trophoblasts originating from human placenta. Binding studies show that the imidazoline site displays a unique pharmacological profile distinct from the α2-adrenoceptor (eg, benzyliden- amino-guanidine, Kj = 18.9 ± 13.8 nmol.L for the imidazoline sites and Kj = 768 ± 299 nmol.L for the a2-adrenoceptors; guanidopyrol, Kj = 11.2 ± 6.3 nmol.L for imidazoline sites and = 10100 ± 1515 nmol.L for the a2-adrenoceptors). A tentative subdivision of the imidazoline sites according to their affinity for amiloride, and the existence of clonidine sites distinct from imidazoline sites are suggested. The question of whether CDS is the natural ligand of the imidazoline or of the clonidine sites is discussed. Am J Hypertens 1992;5:83S-90S.
AB - Many specific hypotensive drugs acting via the central α2-adrenoceptors were designed based on their imidazoline.guanidine structure for use as antihypertensives. This unique structure, which is missing in the α2-adrenoceptor natural ligands, led to the search for an endogenous, nonadrenergic ligand, and later on, for its putative receptor.Indeed, an endogenous ligand designated the "clonidine displacing substance" (CDS), was isolated and purified from bovine brain, and characterized in various cells. The most intriguing feature of CDS is its hypertensive action upon injection into the rostral ventrolateral medulla and its competition with clonidine. Is CDS a natural agonist which is displaced by clonidine or other hypotensive drugs? Does the unique imidazoline.guanidine structure imply a unique recognition site?Recent studies reported that an imidazoline site, distinct from the α2-adrenoceptor, is abundant in many tissues, and it preferentially recognizes the imidazolino-guanidino type ligands.The physiological role of these sites is still not well defined. In the present study we show that the richest tissue in imidazoline sites is human placenta (1800 ± 100 fmol.mg protein). The sites are distributed on the cell surface, as observed in studies of binding to intact cytotrophoblasts and cultured trophoblasts originating from human placenta. Binding studies show that the imidazoline site displays a unique pharmacological profile distinct from the α2-adrenoceptor (eg, benzyliden- amino-guanidine, Kj = 18.9 ± 13.8 nmol.L for the imidazoline sites and Kj = 768 ± 299 nmol.L for the a2-adrenoceptors; guanidopyrol, Kj = 11.2 ± 6.3 nmol.L for imidazoline sites and = 10100 ± 1515 nmol.L for the a2-adrenoceptors). A tentative subdivision of the imidazoline sites according to their affinity for amiloride, and the existence of clonidine sites distinct from imidazoline sites are suggested. The question of whether CDS is the natural ligand of the imidazoline or of the clonidine sites is discussed. Am J Hypertens 1992;5:83S-90S.
KW - Clonidine displacing substance
KW - Imidazoline receptors
KW - α2-Adrenoceptors
UR - http://www.scopus.com/inward/record.url?scp=0026545035&partnerID=8YFLogxK
U2 - 10.1093/ajh/5.4.83S
DO - 10.1093/ajh/5.4.83S
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 1317715
AN - SCOPUS:0026545035
SN - 0895-7061
VL - 5
SP - 83s-90s
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 4
ER -